Bind Research has officially launched as the UK’s first not-for-profit Focused Research Organisation (FRO), dedicated to transforming drug discovery through artificial intelligence and advanced computational techniques. Backed by £12.9 million from the UK Government’s Research Ventures Catalyst programme, alongside funding from Eric Schmidt, NanoTemper, the Chordoma Foundation, and the Klaff Family Foundation, Bind Research aims to unlock new therapeutic avenues for diseases long considered untreatable.
Focusing on disordered proteins, which constitute over 30% of human proteins and play a crucial role in disease mechanisms, Bind Research is developing AI-enhanced tools to characterise these elusive targets and accelerate drug discovery. CEO Gabi Heller stated that the organisation’s mission is to integrate AI with experimental and computational innovations to create public assets that drive scientific breakthroughs.
With an interdisciplinary team of researchers, Bind Research is positioned to bridge academia and industry, ensuring that advances in AI-powered drug discovery translate into tangible treatments for both common and neglected diseases.
